Faeth Therapeutics
FTH
30 hedge funds and large institutions have $68M invested in Faeth Therapeutics in 2026 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
13,104% more capital invested
Capital invested by funds: $515K → $68M (+$67.5M)
1,000% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 2
200% more funds holding
Funds holding: 10 → 30 (+20)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
167.15% more ownership
Funds ownership: 3.83% → 170.97% (+167%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$14.4M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.12M |
| 3 |
Millennium Management
New York
|
+$2.93M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$2.67M |
| 5 |
SC
Stempoint Capital
New York
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$300K |
| 2 |
Citigroup
New York
|
-$3.14K |
| 3 |
BP
BNP Paribas
Paris,
France
|
-$59 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $143K | +$90.5K | +4,529 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $47.2K | +$29.9K | +1,496 | New |
|
28
JP Morgan Chase
New York
| $804 | – | – | – |
|
29
BNP Paribas Financial Markets
Paris,
France
| $284 | – | – | – |
|
|
SS
30
SBI Securities
Tokyo,
Japan
| $126 | – | – | – |
|
|
31
Citigroup
New York
| – | -$3.14K | -294 | Closed |
|
|
BP
32
BNP Paribas
Paris,
France
| – | -$59 | -7 | Closed |
|
FTH Hedge Fund Activity: Q1 2026 in Review
30 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2026, worth a combined $68M — up 13,104% from $515K a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FTH positions and 2 closed out — a net gain of 20 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $14.4M. The largest seller was Ikarian Capital, cutting an estimated $300K.
- 30 institutional investors held Faeth Therapeutics (FTH) as of Q1 2026, up from 10 in Q4 2025.
- Funds reported $68M of Faeth Therapeutics stock for Q1 2026, up 13,104% quarter-over-quarter.
- 22 funds opened new Faeth Therapeutics positions in Q1 2026 and 2 closed out, a net change of +20 holders.
- The largest Faeth Therapeutics buyer in Q1 2026 was Vivo Capital, an estimated $14.4M added.
- The largest Faeth Therapeutics seller in Q1 2026 was Ikarian Capital, an estimated $300K sold.
Based on aggregated 13F filings for Q1 2026.